Funda Meric-Bernstam, Michael W Lloyd, Soner Koc, Yvonne A Evrard, Lisa Meier McShane, Michael T Lewis, Kurt W Evans, Dali Li, Lawrence V Rubinstein, Alana L Welm, Dennis A Dean, Anuj Srivastava, Jeffrey W Grover, Min Jin Ha, Huiqin Chen, Xuelin Huang, Kaushik Varadarajan, Jing Wang, Jack A Roth, Bryan E Welm, Ramaswamy Govindan, Li Ding, Salma Kaochar, Nicholas Mitsiades, Luis G Carvajal-Carmona, Meenhard Herlyn, Michael A Davies, Geoffrey I Shapiro, Ryan C Fields, Jose G Trevino, J Chuck Harrell, James H Doroshow, Jeffrey H Chuang, Jeffrey A Moscow
Although patient-derived xenografts (PDXs) are commonly used for preclinical modeling in cancer research, a standard approach to in vivo tumor growth analysis and assessment of antitumor activity is lacking, complicating comparison of different studies and determination of whether a PDX experiment has produced evidence needed to consider a new therapy promising. We present consensus recommendations for assessment of PDX growth and antitumor activity, providing public access to a suite of tools for in vivo growth analyses...
April 20, 2024: Molecular Cancer Therapeutics